top of page
.jpg)
NEW BOOK
LATEST NEWS
Biogen's Salanersen Shows Promise for SMA Patients Post-Gene Therapy
Biogen’s experimental drug, Salanersen, is showing promising potential for treating children with spinal muscular atrophy (SMA), even...
Jul 1
Sarepta Pauses Duchenne Gene Therapy Trial After Second Patient Death
Sarepta Therapeutics has temporarily halted its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, after a second patient died...
Jul 1
Eli Lilly Acquires Verve Therapeutics to Enhance Cardiovascular Portfolio
Eli Lilly has acquired gene-editing startup Verve Therapeutics for approximately $1 billion, expanding its portfolio to include...
Jul 1
GENE TECH TIMES
The Future Has Arrived
FDA Approves Stem Cell Therapy, Regenecyte, Shown to Help Chemotherapy Patients Recover Blood Count
The FDA has approved Regenecyte, an innovative therapy made from umbilical cord blood stem cells, to help rebuild blood and immune...
Nov 29, 2024
Lenmeldy: The First FDA-Approved Gene Therapy for Metachromatic Leukodystrophy in Children
Lenmeldy , a groundbreaking gene therapy developed by Orchard Therapeutics , has recently received FDA approval , making it the first and...
Apr 15, 2024
bottom of page